Streetbeat News

OPHLY

Ono Pharmaceutical Co. Ltd

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

3.60

Mkt cap

Volume

46K

High

3.60

P/E Ratio

8.07

52-wk high

6.11

Low

3.55

Div yield

0.05

52-wk low

3.52

ONO Pharmaceutical Co., Ltd. has entered into a definitive agreement to acquire Deciphera Pharmaceuticals, aiming to expand its oncology portfolio. This strategic move is expected to enhance ONO's position in the global pharmaceutical market by integrating Deciphera's innovative cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:04 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.